RxDoctor Payments Data

Amy Kubler

Family · Penn Laird, VANPI 1841712957

Payments from drug & device makers

$2,344in general payments, 2019–2025

Across 139 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$503
  • AbbVie$502
  • Novo Nordisk$278
  • AstraZeneca$266
  • Amgen$242
  • Biohaven Pharmaceutical Holding Company Ltd.$153
  • plus $399 from 10 others

What the payments were for

  • Food & beverage$2,344100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,344 in reported general payments places this provider in the 85th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$21,617
Medicare patients
83
Services billed
338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$80,420
JardianceEmpagliflozin35$41,251
Tresiba Flextouch U-200Insulin Degludec12$36,096
FarxigaDapagliflozin Propanediol41$35,910
MounjaroTirzepatide15$26,224
JanuviaSitagliptin Phosphate19$14,493
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$13,732
TrulicityDulaglutide13$12,812
Repatha SureclickEvolocumab12$8,257
PremarinEstrogens, Conjugated28$4,757
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen23$3,603
Desvenlafaxine Succinate ErDesvenlafaxine Succinate36$2,526
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen70$2,482
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,027
Gabapentin94$1,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$278$80,42068 claims
AstraZenecaFarxiga, Breztri Aerosphere$266$49,64255 claims
Boehringer IngelheimJardiance$53$41,25135 claims
Lilly USA, LLCMounjaro, Trulicity$503$39,03628 claims
PfizerPremarin$71$4,75728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,332 family providers in Virginia.

Other family in Penn Laird

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →